Aerobic exercise and nano-curcumin supplementation improve inflammation in elderly females with metabolic syndrome

Abstract Background Aging, inflammation, oxidative stress, and metabolic syndrome are the main important factors in brain-derived neurotrophic factor (BDNF) level. Aim The aim of this research was to investigate the effect of 6-week aerobic exercise with moderate intensity and consumption of nano-curcumin on IL-6, IL-10 and BDNF in 60–65 year females with metabolic syndrome (MS). Materials and methods Forty-four women with metabolic syndrome (Mets) voluntarily took part in the present study. Participants were randomly divided into 4 groups of MetS exercise + Nano-Curcumin (MENC), MetS exercise (ME), MetS Nano-Curcumin (MNC), MetS control (MC). During the first week, MENC and ME groups participated in three sets of 10-min aerobic exercise training (AT) with a treadmill with 5-min rest parts between the sets. One minute was added to the duration of exercise sets weekly. Blood samples were collected before and after 6 weeks. IL-6, IL-10 and BDNF levels were measured by ELISA method. To analyze the data, Paired-samples t-test with the significance level of (P ≤ 0.05). Results IL-10 and BDNF concentrations significantly increased after a 6-week intervention (P ≤ 0.05). Also, IL-6 serum levels significantly decreased (P ≤ 0.05). Besides, the results of the present study suggested that nano-curcumin supplementation significantly decreases serum concentrations of malondialdehyde (MDA), and hs-CRP in subjects with metabolic syndrome. In addition, the results of the present study suggested that nano-curcumin supplementation significantly increases serum concentrations of BDNF, IL-10, and total antioxidant capacity (TAC) in subjects with metabolic syndrome. Conclusion Findings show that both of the regular exercise and consumption of NanoCurcumin for 6 weeks reduce inflammation. Combination of these two leads to even more reduction of inflammation. The regular exercise led to a decrease at the fat percentage, which deceased IL-6 level and increased IL-10 level. So, this change led to increasing BDNF’s levels. Trial registration IRCT2017082335857N1 Registered 2017-11-16, https://en.irct.ir/trial/26971